BRAF and melanoma: In conclusion, we have assessed the responses of a series of 44 melanoma lines, generally of low passage number, to CI-1040, a prototypic MEK inhibitor, as well as to trametinib, a clinical MEK inhibitor and vemurafenib, a clinical BRAF inhibitor.